You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 20102059 THE EFFECT OF DEMOGRAPHIC AND CLINICAL FACTORS ON THE RELATIONSHIP BETWEEN BMI AND PSA LEVELS Jonathan L. Wright, Daniel W. Lin, and Janet L. Stanford Jonathan L. WrightJonathan L. Wright More articles by this author , Daniel W. LinDaniel W. Lin More articles by this author , and Janet L. StanfordJanet L. Stanford More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.2106AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Studies have reported lower prostate specific antigen (PSA) levels in men with a higher body mass index (BMI). Additional demographic and clinical factors may also affect PSA levels and are related to obesity, including diabetes mellitus (DM), benign prostatic hyperplasia (BPH) and certain medications (e.g., statins, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs)). In this study, we determine whether, when controlling for BMI, other factors are independently associated with PSA levels in healthy men. METHODS 787 controls from a population-based case-control study of prostate cancer (PCa) comprised the study cohort. PSAs were drawn at time of interview and log-transformed for analysis. Demographics and medical history were obtained. Participants were asked specifically about statin, NSAID and aspirin use. BMI was categorized (<25, 25″C29, ¡Ý30) and age-adjusted linear regression used to predict geometric mean PSA level. A multivariate stepwise regression model was used to explore potential confounders (race, family history of PCa (FH), BPH, DM and current medication use). RESULTS With increasing BMI (<25, 25″C29, ¡Ý30), the geometric mean PSA level declined (1.20, 1.14, 0.91 respectively) and obese men had a 20% reduction in geometric mean PSA compared to those with normal weight (95% CI 67%″C95%), adjusting for age. Multiple variables were statistically significantly associated with decreases (statin use, aspirin use, DM) or increases (BPH, FH) in the age-adjusted geometric mean PSA level. In the multivariate model, BMI was associated with a non-significant decrease in geometric mean PSA (p-trend = 0.06). A significant increase in geometric mean PSA was observed for both BPH ((ratio of geometric means (RGM) = 1.42, 95% CI 1.21 ″C 1.66) and a FH of PCa (RGM = 1.22, 95% CI 1.00 ″C 1.48). Current use of statins was associated with a 19% reduction in the geometric mean PSA (RGM = 0.81, 95% CI 0.70 ″C 0.95). CONCLUSIONS A number of factors independently altered the geometric mean PSA levels in men without a history of PCa. Statin use was independently associated with a 19% reduction in geometric mean PSA, while the effect of BMI on PSA was not significant when adjusting for confounders. Age, BPH and FH of PCa were associated with increased PSA levels. These results should help in interpreting PSA values in men undergoing screening for PCa. Seattle, WA© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e800 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jonathan L. Wright More articles by this author Daniel W. Lin More articles by this author Janet L. Stanford More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...